PASG Stock Overview
A genetic medicines company, develops gene therapies for central nervous system diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Passage Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.70 |
| 52 Week High | US$1.79 |
| 52 Week Low | US$0.45 |
| Beta | 1.54 |
| 1 Month Change | -9.68% |
| 3 Month Change | 22.81% |
| 1 Year Change | -39.66% |
| 3 Year Change | -87.78% |
| 5 Year Change | n/a |
| Change since IPO | -96.85% |
Recent News & Updates
Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?
Jan 07
Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?
Sep 24Recent updates
Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?
Jan 07Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?
Sep 24Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?
Jun 11We're Keeping An Eye On Passage Bio's (NASDAQ:PASG) Cash Burn Rate
Feb 27Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?
Nov 13We Think Passage Bio (NASDAQ:PASG) Needs To Drive Business Growth Carefully
Jun 23Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?
Nov 13Passage appoints William Chou CEO
Oct 10Passage Bio GAAP EPS of -$0.73 beats by $0.09
Aug 04We're A Little Worried About Passage Bio's (NASDAQ:PASG) Cash Burn Rate
Jun 03Passage Bio: Worth Keeping An Eye On
Apr 11Will Passage Bio (NASDAQ:PASG) Spend Its Cash Wisely?
Dec 15Passage Bio (NASDAQ:PASG) Is In A Good Position To Deliver On Growth Plans
Aug 19Passage Bio: Price Reduced, But Without Data, Does Not Look Convincing
Jun 06Passage Bio partners with InformedDNA to offer counseling, testing for early dementia
May 03We're Hopeful That Passage Bio (NASDAQ:PASG) Will Use Its Cash Wisely
Mar 08Do Institutions Own Passage Bio, Inc. (NASDAQ:PASG) Shares?
Feb 01
Passage Bio on go with PBGM01 gene therapy trial in the U.S.
Jan 04Need To Know: Passage Bio, Inc. (NASDAQ:PASG) Insiders Have Been Buying Shares
Dec 28U.K. authorizes Passage Bio's PBGM01 trial
Dec 10Passage Bio (PASG) Investor Presentation - Slideshow
Nov 16Passage Bio EPS beats by $0.13
Nov 10Passage Bio’s PBKR03 nabs Orphan drug tag and accelerated review status for Krabbe disease
Oct 28Shareholder Returns
| PASG | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 23.4% | 1.6% | 1.3% |
| 1Y | -39.7% | -7.2% | 24.4% |
Return vs Industry: PASG underperformed the US Biotechs industry which returned -7.2% over the past year.
Return vs Market: PASG underperformed the US Market which returned 24.4% over the past year.
Price Volatility
| PASG volatility | |
|---|---|
| PASG Average Weekly Movement | 28.8% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: PASG's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PASG's weekly volatility has increased from 18% to 29% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 58 | Will Chou | www.passagebio.com |
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington’s disease.
Passage Bio, Inc. Fundamentals Summary
| PASG fundamental statistics | |
|---|---|
| Market cap | US$47.19m |
| Earnings (TTM) | -US$68.80m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs PASG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PASG income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$68.80m |
| Earnings | -US$68.80m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.11 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PASG perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/07 23:39 |
| End of Day Share Price | 2025/01/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Passage Bio, Inc. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yun Zhong | BTIG |
| Whitney Ijem | Canaccord Genuity |
| Yevgeniya Livshits | Chardan Capital Markets, LLC |